Featured Publications
Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study
Henneges C, Jin D, Venstrom J, Trabucco S, Nielsen T, Penuel E, Huet S, Salles G, Paulson J. Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study. Blood 2020, 136: 25-26. DOI: 10.1182/blood-2020-134795.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaDe novo diffuse large B-cell lymphomaProgression-free survivalTumor mutational burdenComprehensive genomic profilingCurrent equity holderAssociated with progression-free survivalFollicular lymphomaF. Hoffmann-La RocheFoundation MedicinePrognostic valueClinical outcomesMedian tumor mutation burdenProgression-free survival eventsPooled analysis of patientsLarge B-cell lymphomaResponse to induction treatmentCalculate tumor mutational burdenAssociated with clinical outcomesEZH2 mutation statusComprehensive genomic profiling dataB-cell lymphomaGenetic mutational landscapeAnalysis of patientsProportion of patients
2022
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma
Thieblemont C, Chartier L, Dührsen U, Vitolo U, Barrington S, Zaucha J, Vercellino L, Silva M, Patrocinio-Carvalho I, Decazes P, Viailly P, Tilly H, Berriolo-Riedinger A, Casasnovas O, Hüttmann A, Ilyas H, Mikhaeel N, Dunn J, Cottereau A, Schmitz C, Kostakoglu L, Paulson J, Nielsen T, Meignan M. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma. Blood Advances 2022, 6: 5995-6004. PMID: 36044385, PMCID: PMC9691911, DOI: 10.1182/bloodadvances.2021006923.Peer-Reviewed Original ResearchConceptsLarge B-cell lymphomaAggressive large B-cell lymphomaB-cell lymphomaRisk factorsTumor volumePerformance statusDiffuse large B-cell lymphomaInternational Prognostic IndexMetabolic tumor volumeProgression-free survivalReal-world seriesReal-world clinicsREMARC trialOverall survivalRefractory diseaseECOG-PSPrognostic indexIntermediate riskInitial treatmentTreatment initiationRisk stratificationC-indexOlder patientsPrognostic toolClinical trialsFull automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments
Jemaa S, Paulson J, Hutchings M, Kostakoglu L, Trotman J, Tracy S, de Crespigny A, Carano R, El-Galaly T, Nielsen T, Bengtsson T. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. Cancer Imaging 2022, 22: 39. PMID: 35962459, PMCID: PMC9373298, DOI: 10.1186/s40644-022-00476-0.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaProgression-free survivalOverall survivalFDG-PETUntreated diffuse large B-cell lymphomaHazard ratioHigh-risk DLBCL patientsCentral nervous system relapseLarge B-cell lymphomaMetabolic tumor volumeImaging-based risk factorsB-cell lymphomaEnhanced risk stratificationHigh-risk populationImaging metricsRisk increaseDLBCL patientsFDG-PET/CTSystemic relapseTumor volumeOrgan involvementPrognostic improvementRisk stratificationInvasive proceduresClinical dataOutcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial.
Morschhauser F, Jiang Y, Jardin F, Herrera A, Sehn L, Herbaux C, Flowers C, Phillips T, Guillermo A, Diefenbach C, Gregory G, Kim A, Barbui A, Balasubramanian S, Harris W, Hirata J, Paulson J, Lee C, Lenz G. Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial. Journal Of Clinical Oncology 2022, 40: 7517-7517. DOI: 10.1200/jco.2022.40.16_suppl.7517.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaPola-R-CHPProgression-free survivalR-CHOPPrognostic impactMultivariate analysisBCL6-RUntreated diffuse large B-cell lymphomaProgression-free survival eventsProgression-free survival estimatesLarge B-cell lymphomaMultivariate Cox regression modelDouble expressor lymphomaSubgroups of ptsTranslocation of MYCTriple-hit lymphomaAssociated with poor outcomesB-cell lymphomaMYC protein expressionResults of univariate analysisCox regression modelsBCL2+Cell of originOverexpression of BCL2Fluorescence in situ hybridizationP1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).
Jiang Y, Jin D, Henneges C, Penuel E, Hiew H, Paulson J, Bazeos A. P1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). HemaSphere 2022, 6: 1153-1154. PMCID: PMC9429719, DOI: 10.1097/01.hs9.0000847936.41396.29.Peer-Reviewed Original ResearchPatient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study
Huang H, Datye A, Fan M, Knapp A, Nielsen T, Bottos A, Paulson J, Trask P, Efficace F. Patient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study. Cancer Medicine 2022, 11: 3312-3322. PMID: 35322932, PMCID: PMC9468432, DOI: 10.1002/cam4.4692.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaInternational Prognostic IndexProgression-free survivalLarge B-cell lymphomaB-cell lymphomaOverall survivalPrognostic valuePatient-reported outcomesPrognostic informationCox regression analysis of overall survivalClinical variablesAnalysis of overall survivalPhase III studyFifty-nine patientsCox regression analysisPatient risk stratificationPopulation of patientsEuropean Organization for Research and Treatment of Cancer Quality of LifeEuropean Organization for Research and TreatmentPlus chemotherapyIII studiesPrognostic indexTreatment of Cancer Quality of LifeGlobal health status/quality of lifeGlobal health status/qualityRisk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
Herrera A, Tracy S, Croft B, Opat S, Ray J, Lovejoy A, Musick L, Paulson J, Sehn L, Jiang Y. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Advances 2022, 6: 1651-1660. PMID: 35086141, PMCID: PMC8941482, DOI: 10.1182/bloodadvances.2021006415.Peer-Reviewed Original ResearchConceptsCirculating tumor DNAInternational Prognostic IndexProgression-free survivalBaseline circulating tumour DNAEnd of treatmentOverall survivalR/R DLBCLComplete responseTumor DNARelapsed/refractory diffuse large B-cell lymphomaDiffuse large B-cell lymphomaMeasuring circulating tumor DNAShorter progression-free survivalLarge B-cell lymphomaHigh risk of progressionCirculating tumour DNA assaysLactate dehydrogenaseBaseline ctDNA levelRisk profile of patientsB-cell lymphomaRisk of relapseRisk of progressionSerum lactate dehydrogenaseProfile of patientsCtDNA assessmentPrognostic mutational subtyping in de novo diffuse large B-cell lymphoma
Kim E, Jiang Y, Xu T, Bazeos A, Knapp A, Bolen C, Humphrey K, Nielsen T, Penuel E, Paulson J. Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma. BMC Cancer 2022, 22: 231. PMID: 35236331, PMCID: PMC8892802, DOI: 10.1186/s12885-022-09237-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicEnhancer of Zeste Homolog 2 ProteinExome SequencingFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedMutationPrognosisProto-Oncogene Proteins c-bcl-2RNA-SeqSulfonamidesTreatment OutcomeConceptsSequence dataWhole-exome sequencing dataExome-sequencing dataTargeted sequencing platformsExome sequencing dataTargeted sequencing dataBackgroundDiffuse large B-cell lymphomaLarge B-cell lymphomaSequencing platformsRNA-seqDe novo DLBCLImproved overall survivalTarget sequenceB-cell lymphomaVenetoclax therapyMutation subtypesPrognostic subsetsMutationsOverall survivalMolecular subsetsSubset distributionMutation groupSurvival outcomesMutation profilesClinical associationsTRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma
Harris W, Bataillard E, Choi Y, El-Galaly T, Cuchelkar V, Henneges C, Kwan A, Schneider D, Paulson J, Nielsen T. TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma. JCO Clinical Cancer Informatics 2022, 6: e2100121. PMID: 35044836, DOI: 10.1200/cci.21.00121.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaR-CHOPFirst-line treatment of diffuse large B-cell lymphomaDiagnosed DLBCLTreatment of diffuse large B-cell lymphomaCourses of R-CHOPPresence of cardiovascular diseaseFirst-line treatmentProportion of patientsArea under the curveRoutine clinical settingCharlson Comorbidity IndexStandard of careHigh-risk categoryStandard chemoimmunotherapyChemotherapy toxicityCreatinine clearanceInferior outcomesBaseline characteristicsLogistic regression modelsComorbidity indexPatient frailtyEnd points
2020
The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World
Thieblemont C, Chartier L, Dührsen U, Vitolo U, Barrington S, Vercellino L, Zaucha J, Carvalho I, da Silva Maria G, Decazes P, Viailly P, Tilly H, Berriolo-Riedinger A, Casasnovas R, Hüttmann A, Ilyas H, Mikhaeel G, Dunn J, Cottereau A, Schmitz C, Paulson J, Nielsen T, Meignan M. The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World. Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-136544.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaLarge B-cell lymphomaMetabolic tumor volumeProgression-free survivalB-cell lymphomaClinical trialsR-CHOPOverall survivalTumor volumeNewly diagnosed diffuse large B-cell lymphomaTotal metabolic tumor volumeStandard of careECOG PSCurative intentImmuno-chemotherapyPatientsMultiple centersEarly identificationCohortLymphomaTrialsSurvivalMultiple cohortsBaselineTMTVAbstract 2035: Listen to the patients: Assessing the prognostic value of pre-treatment health-related quality of life in 1L DLBCL patients
Huang H, Datye A, Fan M, Knapp A, Balakrishnan R, Balasubramanian S, Chae J, Roth E, Nielsen T, Paulson J, Trask P. Abstract 2035: Listen to the patients: Assessing the prognostic value of pre-treatment health-related quality of life in 1L DLBCL patients. Cancer Research 2020, 80: 2035-2035. DOI: 10.1158/1538-7445.am2020-2035.Peer-Reviewed Original ResearchDiffuse large B-cell lymphoma patientsDiffuse large B-cell lymphomaInternational Prognostic IndexProgression free survivalPre-treatment HRQOLPrognostic valueOverall survivalHealth-related quality of lifePatient-reported health-related quality-of-lifeAssociated with better survival outcomesLarge B-cell lymphomaHigh risk of progressionQuality of lifeAnn Arbor stageB-cell lymphomaBetter survival outcomesKaplan-Meier methodAmerican Association for Cancer ResearchContribution to prognosisImprove risk stratificationCox proportional hazards modelsNovel treatment strategiesHRQOL subscale scoresStatus of patientsInformed treatment decisions
2019
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study
Bolen C, Klanova M, Trneny M, Sehn L, He J, Tong J, Paulson J, Kim E, Vitolo U, Di Rocco A, Fingerle-Rowson G, Nielsen T, Lenz G, Oestergaard M. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. Haematologica 2019, 105: 2298-2307. PMID: 33054054, PMCID: PMC7556630, DOI: 10.3324/haematol.2019.227892.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaPrognostic impact of somatic mutationsCell-of-origin subtypesBCL2 alterationsCell of originPrognostic impactImpact of somatic mutationsMolecular heterogeneity of diffuse large B-cell lymphomaGerminal center B-cell-like diffuse large B-cell lymphomaHeterogeneity of diffuse large B-cell lymphomaTargeted DNA next-generation sequencingAssociated with shorter progression-free survivalShorter progression-free survivalSomatic mutationsDNA next-generation sequencingParaffin-embedded tissue biopsiesProgression-free survivalMultivariate Cox regressionBCL2 translocationsUntreated patientsPotential treatment targetPrognostic differencesPrognostic effectRecapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL
Kim E, Fan J, Bolen C, Bazeos A, Jiang Y, Balasubramanian S, Balakrishnan R, Knapp A, Humphrey K, Nielsen T, Venstrom J, Hernandez G, Paulson J. Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL. Blood 2019, 134: 2788. DOI: 10.1182/blood-2019-124687.Peer-Reviewed Original ResearchWhole-exome sequencingDiffuse large B-cell lymphomaExome-sequencing dataInternational Prognostic IndexBCL2 inhibitor venetoclaxHigh-risk groupRNA gene expression dataGene expression dataTargeted therapyClinical outcomesCopy number amplificationNext-generation sequencingDe novo diffuse large B-cell lymphomaAssociated with inferior clinical outcomesLarge B-cell lymphomaGenetic risk modelsNucleotide variantsAdverse prognostic impactClinical prognostic scoresB-cell lymphomaInferior clinical outcomesImprove survival outcomesExpression dataExome sequencingClinically heterogeneous diseasePolatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn L, Herrera A, Flowers C, Kamdar M, McMillan A, Hertzberg M, Assouline S, Kim T, Kim W, Ozcan M, Hirata J, Penuel E, Paulson J, Cheng J, Ku G, Matasar M. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal Of Clinical Oncology 2019, 38: 155-165. PMID: 31693429, PMCID: PMC7032881, DOI: 10.1200/jco.19.00172.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBiomarkers, TumorFemaleHumansImmunoconjugatesImmunohistochemistryLymphoma, Large B-Cell, DiffuseMaleMiddle AgedProgression-Free SurvivalSurvival RateConceptsProgression-free survivalLarge B-cell lymphomaPolatuzumab vedotinB-cell lymphomaCR rateOverall survivalPola-BRR/R DLBCLRefractory diffuse large B-cell lymphomaIRC-assessed progression-free survivalDiffuse large B-cell lymphomaB-cell receptor componentsSingle-arm cohortsDuration of responseCohort of patientsCox regression methodRisk of deathMedian OSSafety profileKaplan-MeierTreatment optionsB cellsPolatuzumabBendamustineDLBCLS845 PREDICTED NEOANTIGENS PROVIDE PROGNOSTIC INSIGHT IN DLBCL
Paulson J, Jin D, Sokol E, Nielsen T, Venstrom J, Trabucco S. S845 PREDICTED NEOANTIGENS PROVIDE PROGNOSTIC INSIGHT IN DLBCL. HemaSphere 2019, 3: 377. DOI: 10.1097/01.hs9.0000561660.80605.a5.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaTumor mutational burdenComprehensive genomic profilingNeoantigen burdenImmune surveillanceClinical outcomesPrognostic insightsPoor outcomeEstimate tumor mutation burdenMedian tumor mutation burdenPersonalized cancer vaccine strategiesHigh tumor mutational burdenLarge B-cell lymphomaEvasion of immune surveillanceVaccination strategiesCancer vaccine strategiesAssociated with worsened outcomesB-cell lymphomaMultivariate Cox regressionImpact clinical outcomesCell of originMHC-I presentationBCL2 alterationsDLBCL cohortPrognostic factors